| Literature DB >> 18511877 |
Kanako Yamanaka1, Yasuhiro Ito, Noriko Okuyama, Katsuhisa Noda, Hitoshi Matsumoto, Hiroshi Yoshida, Akira Miyauchi, Mariana Capurro, Jorge Filmus, Eiji Miyoshi.
Abstract
In 123 patients with thyroid cancer, expression of glypican 3 (GPC3) was immunohistochemically investigated in tissue samples and the biological significance of GPC3 in thyroid cancer was examined. GPC3 was scarcely expressed in the normal thyroid gland, but was dramatically enhanced in certain types of cancers: 100% in follicular carcinoma (20/20 cases) and 70% in papillary carcinoma (48/69 cases). Expression of GPC3 in follicular carcinoma was significantly higher than that of follicular adenoma (p < 0.0019). In contrast, GPC 3 was not expressed in 17 cases of anaplastic carcinoma. A high expression of GPC3 mRNA was confirmed in cancer lesions, which were strongly positive for immunohistochemical staining. In 69 cases of papillary carcinoma, GPC3 was expressed at an early stage, suggesting that GPC3 expression in thyroid cancer is an early event in developing papillary carcinoma. Further studies are required to determine biological functions and molecular mechanisms underlying the upregulation of GPC3 in thyroid cancer. 2008 S. Karger AG, Basel.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18511877 DOI： 10.1159/000136159
Source DB: PubMed Journal: Oncology ISSN： 0030-2414 Impact factor: 2.935